Epigenomics AG N
Frankfurt Stock ExchangeTotal Valuation
Epigenomics AG N carries a market capitalization of 762,946.00, placing it among publicly traded companies globally. Its enterprise value stands at 36,879.03, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 762,946.00 |
| Enterprise Value | 36,879.03 |
Share Statistics
Epigenomics AG N currently has 853,285.00 shares outstanding.
| Shares Outstanding | 853,285.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 7.29, and the price-to-book ratio stands at -0.03.
| PE Ratio | N/A |
| PS Ratio | 7.29 |
| PB Ratio | -0.03 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | -0.38 |
| P/OCF Ratio | -0.34 |
Enterprise Valuation
| EV / Sales | 0.08 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Epigenomics AG N maintains a current ratio of 1.93, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.65, indicating elevated leverage, while an interest coverage ratio of -180.60 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.93 |
| Quick Ratio | 1.67 |
| Debt / Equity | 18.65 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -180.60 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -131.18 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.73 |
Taxes
| Income Tax | -77,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Epigenomics AG N's stock has gained approximately 58.18182% over the past 52 weeks. The 50-day moving average sits at 0.91, while the 200-day moving average is 0.92.
| Beta (5Y) | N/A |
| 52-Week Price Change | 58.18182% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 0.92 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Epigenomics AG N generated 448,000.00 in revenue and converted that into -16.29M in net income, yielding earnings per share of -19.36. EBITDA reached -18.24M, while operating income came in at -18.24M.
| Revenue | 448,000.00 |
| Gross Profit | 343,000.00 |
| Operating Income | -18.24M |
| Pretax Income | -16.37M |
| Net Income | -16.29M |
| EBITDA | -18.24M |
| EBIT | -18.24M |
| Earnings Per Share (EPS) | -19.36 |
Balance Sheet
Epigenomics AG N holds 3.58M in cash and equivalents against 356,000.00 in total debt, resulting in a net debt position of -3.58M. Total book value stands at -100.37M, with working capital of 2.01M providing operational flexibility.
| Cash & Cash Equivalents | 3.58M |
| Total Debt | 356,000.00 |
| Net Debt | -3.58M |
| Equity (Book Value) | -100.37M |
| Book Value Per Share | -119.28 |
| Working Capital | 2.01M |
Cash Flow
Epigenomics AG N produced -9.57M in operating cash flow over the past twelve months. After subtracting -1.03M in capital expenditures, free cash flow totaled -10.60M - equivalent to -12.60 per share.
| Operating Cash Flow | -9.57M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -10.60M |
| FCF Per Share | -12.60 |
Margins
Epigenomics AG N operates with a gross margin of 76.56, reflecting its pricing power and cost economics. The operating margin of -4,071.65 and net profit margin of -3,636.16 provide insight into operational efficiency.
| Gross Margin | 76.56 |
| Operating Margin | -4,071.65 |
| Pretax Margin | -3,653.35 |
| Profit Margin | -3,636.16 |
| EBITDA Margin | -4,071.65 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 3.71 |
| FCF Yield | -261.57 |
Scores
Epigenomics AG N posts an Altman Z-Score of -48.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -48.11 |